FULCRUM THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
FULCRUM THERAPEUTICS, INC. (FULC) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $12.00 million as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-09-02
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $12.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $5.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $5.70M.
- 2021-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $12.00M S-4 · filed 2026-09-02 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-04-27 |
| 2025-09-30 | $5.70M 10-Q · filed 2025-10-29 |
| 2021-12-31 | $0.00 10-K/A · filed 2023-06-26 |
| 2020-12-31 | $3.10M 10-K/A · filed 2023-06-23 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-11 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |